Cellectar BioSciences, Inc.

Summary

Profile

Financials

Events

Ownership

Options

Company Info

Industry	Biotechnology
Sector	Health Technology
Employees	11
CEO	Mr. James V. Caruso

Address	100 Campus Drive , Florham Park, NJ 07932
Phone	1.608.441.8120
Website	www.cellectar.com

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detects tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.

Competitors

Company Name	3 Month %Change	1 Year %Change
Cellectar BioSciences, Inc.	-27.26%	-45.16%
Generation Bio Co.	-32.34%	-60.31%
ViewRay, Inc.	-12.14%	33.85%
Nuvalent, Inc.	-40.16%	n/a
BellRing Brands, Inc.	-28.55%	2.62%

Statement Summary

as of 4:00 ET PM 11/29/2021

Total Assets (MRQ)	42.0 M
Total Liabilities (MRQ)	3.4 M
Shareholders’ Equity (MRQ)	38.6 M
Total Revenue (Annual)	n/a
Net Income (Annual)	-5.8 M

Earnings And Estimates

as of 4:00 ET PM 11/29/2021

Current Qtr EPS Estimate	-0.10
Current FY EPS Estimate	-0.44
Long Term EPS Growth Estimate	14.00
Next Expected Earnings Date	//

CLRB vs S&P 500

as of 11/29/2021

	Relative To S&P 500	CLRB
4 Weeks	n/a	n/a
12 Weeks	n/a	n/a
YTD	n/a	n/a

Earnings Surprises

as of 4:00 ET PM 11/29/2021

Fiscal Quarter	Estimate	Actual	Surprise
09/2021	-0.11	-0.10	-4.76%
06/2021	-0.12	-0.11	-4.35%
03/2021	-0.10	-0.13	+32.65%
12/2020	-0.14	0.07	-149.30%
09/2020	-0.20	-0.15	-25.00%
06/2020	-0.28	-0.26	-8.45%
03/2020	-0.35	-0.42	+21.15%
12/2019	-0.37	-0.36	-2.68%

Financial Strength

as of 4:00 ET PM 11/29/2021

Pre-Tax Margin	0.00
Net Margin	0.00
Operating Margin	0.00
Return On Equity	-79.62
Return On Assets	-69.65
Inventory Turnover (TTM)	0.00
Sales Growth (MRQ)	n/a

Ratios

as of 4:00 PM ET 11/29/2021

Price/Earnings (TTM)	n/a
Price/Book (MRQ)	1.14
Price/Cash Flow (TTM)	0.00
Book Value (MRQ)	0.61
Quick Ratio (MRQ)	13.07
Current Ratio (MRQ)	13.07
Total Debt/Equity (MRQ)	0.01

Short Interest

as of 4:00 PM ET 11/30/2021

	% Short - 0.00%
	% Remaining Float - 100.00%

	Current	Last Month
Short Interest Date	n/a	n/a
Short Interest Shares	0	0
Short Interest Ratio	0.0	0.0

M Y M Y

Total Assets 0,0.00 0,0.00

Total Liabilities 0,0.00 0,0.00

Total Equity 0,0.00 0,0.00

M Y M Y

Total Revenue 0,0.00 0,0.00

EBT Exc.
Unusual Items 0,0.00 0,0.00

Net Income 0,0.00 0,0.00

M Y M Y

Cash from
Operations 0,0.00 0,0.00

Cash from
Activities 0,0.00 0,0.00

Cash from
Fin. Activities 0,0.00 0,0.00

Select Period

TOTAL ASSETS	TOTAL LIABILITIES	TOTAL EQUITY

Balance Sheet

	M Y
ASSETS
Cash And Equivalents	0,0.00
Receivables	0,0.00
Inventories	0,0.00
Other Current Assets	0,0.00
Total Current Assets	0,0.00
Property, Plant & Equipment, Gross	0,0.00
Accumulated Depreciation & Depletion	0,0.00
Property, Plant & Equipment, Net	0,0.00
Intangibles	0,0.00
Other Non-Current Assets	0,0.00
Total Non-Current Assets	0,0.00
TOTAL ASSETS	0,0.00
Liabilities & Shareholder Equity
Accounts Payable	0,0.00
Short Term Debt	0,0.00
Total Current Liabilities	0,0.00
Long Term Debt	0,0.00
Deferred Income Taxes	0,0.00
Other Non-Current Liabilities	0,0.00
Minority Interest	0,0.00
Total Non-Current Liabilities	0,0.00
Preferred Stock Equity	0,0.00
Common Stock Equity	0,0.00
Common Par	0,0.00
Additional Paid In Capital	0,0.00
Cumulative Translation Adjustment	0,0.00
Retained Earnings	0,0.00
Treasury Stock	0,0.00
Other Equity Adjustments	0,0.00
Total Capitalization	0,0.00
TOTAL EQUITY	0,0.00
TOTAL LIABILITIES & STOCK EQUITY	0,0.00
Total Common Shares Outstanding	0,0.00
Preferred Shares	0,0.00
Treasury Shares	0,0.00
Basic Weighted Shares Outstanding	0,0.00
Diluted Weighted Shares Outstanding	0,0.00
Number Of Employees	0,0.00
Number Of Part-Time Employees	0,0.00

Select Period

TOTAL REVENUES	EBT Excluding Unusual Items	NET INCOME

Income Statement

	M Y
Sales	0,0.00
Cost Of Sales	0,0.00
Gross Operating Profit	0,0.00
Selling, General, And Administrative Expenses	0,0.00
Research & Development	0,0.00
Operating Income Before D & A (EBITDA)	0,0.00
Depreciation & Amortization	0,0.00
Interest Income	0,0.00
Other Income - Net	0,0.00
Special Income / Charges	0,0.00
Total Income Before Interest Expenses (EBIT)	0,0.00
Interest Expense	0,0.00
Pre-Tax Income	0,0.00
Income Taxes	0,0.00
Minority Interest	0,0.00
Net Income From Continuing Operations	0,0.00
Net Income From Discontinued Operations	0,0.00
Net Income From Total Operations	0,0.00
Extraordinary Income/Losses	0,0.00
Income From Cum. Effect Of Acct. Change	0,0.00
Income From Tax Loss Carryforward	0,0.00
Other Gains / Losses	0,0.00
Total Net Income	0,0.00
Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge)	0,0.00
Preferred Dividends	0,0.00
Net Income Available To Common	0,0.00
Basic EPS From Continuing Ops.	0,0.00
Basic EPS From Discontinued Ops.	0,0.00
Basic EPS From Total Operations	0,0.00
Basic EPS From Extraordinary Inc.	0,0.00
Basic EPS From Cum Effect Of Accounting Change	0,0.00
Basic EPS From Tax Loss Carryf'd.	0,0.00
Basic EPS From Other Gains (Losses)	0,0.00
Basic EPS, Total	0,0.00
Basic Normalized Net Income/Share	0,0.00
EPS From Continuing Ops.	0,0.00
EPS From Discontinued Ops	0,0.00
EPS From Total Ops.	0,0.00
EPS From Extraord. Inc.	0,0.00
EPS From Cum Effect of Accounting Change	0,0.00
EPS From Tax Loss Carfd.	0,0.00
EPS From Other Gains (L)	0,0.00
EPS, Total	0,0.00
Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge)	0,0.00
Dividends Paid Per Share	0,0.00

Select Period

CASH FROM OPERATIONS	CASH FROM INVESTING ACTIVITIES	CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

	M Y
Cash Flow From Operating Activities
Net Income (Loss)	0,0.00
Operating Gains/Losses	0,0.00
Gross Operating Profit	0,0.00
(Increase) Decrease In Receivables	0,0.00
(Increase) Decrease In Inventories	0,0.00
(Increase) Decrease In Other Current Assets	0,0.00
(Decrease) Increase In Other Current Liabilities	0,0.00
(Increase) Decrease In Other Working Capital	0,0.00
Other Non-Cash Items	0,0.00
Net Cash From Continuing Operations	0,0.00
Net Cash From Discontinued Operations	0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities	0,0.00
Sale Of Property, Plant & Equipment	0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments	0,0.00
Purchases Of Property, Plant & Equipment	0,0.00
Acquisitions	0,0.00
Purchases Of Short-Term Investments	0,0.00
Other Cash From Investing Activities	0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities	0,0.00
Issuance Of Debt	0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock	0,0.00
Repayment Of Long-Term Debt	0,0.00
Repurchase Of Capital Stock	0,0.00
Payment Of Cash Dividends	0,0.00
Other Financing Charges, Net	0,0.00
Net Cash From Financing Activities	0,0.00
Effect Of Exchange Rate Changes	0,0.00
Net Change In Cash & Cash Equivalents	0,0.00

Earnings Estimates

as of 4:00 ET PM 11/29/2021

	Current Qtr (12/2021)	Next Qtr (03/2022)
Consensus Estimate	$-0.10	$-0.11
# of Estimates	3	2
High Estimate	$-0.10	$-0.10
Low Estimate	$-0.11	$-0.11
Year Ago EPS	$-0.08	$-0.13
Year Over Year Growth Estimate	29.82%	-20.51%

	Current Yr (12/2021)	Next Yr (12/2022)
Consensus Estimate	$-0.44	$-0.44
# of Estimates	3	3
High Estimate	$-0.44	$-0.39
Low Estimate	$-0.45	$-0.53
Year Ago EPS	$-0.76	$-0.44
Year Over Year Growth Estimate	-41.67%	0.00%

	Current Qtr (12/2021)	Next Qtr (03/2022)	Current Year (12/2021)	Next Year (12/2022)
Consensus Estimate	$-0.10	$-0.11	$-0.44	$-0.44
# of Estimates	3	2	3	3
High Estimate	$-0.10	$-0.10	$-0.44	$-0.39
Low Estimate	$-0.11	$-0.11	$-0.45	$-0.53
Year Ago EPS	$-0.08	$-0.13	$-0.76	$-0.44
Year Over Year Growth Estimate	29.82%	-20.51%	-41.67%	0.00%

Insider Information Summary

as of 10/31/2021

	% Insiders - 8.92%
	% Remaining Total Shares - 91.08%

	Current	1 Month
Net Insider Transaction	44.42 K	44.42 K
Shares Bought	44.42 K	44.42 K
Shares Sold	0.00	0.00

Insider Activity

Purchases

Sales

Options Exercised

Options Awarded

Transaction Date	Insider/Title	Transaction Type	Market Value	Shares	Average Price	Current Holdings

Learn to Trade Like a Pro

Master The Market with the Help of Our Financial Experts

SUBSCRIBE NOW

Perilous Reversal Watch: Golar LNG (GLNG)

MARKETS

CLRB SKBI MGCD

By TheStreet Wire

Aug 21, 2015 4:34 PM EDT

Latest News

Barbarian At The Gate: Annaly Capital Management (NLY)

Aug 11, 2015 4:34 PM EDT

Insider Trading Alert - DUK, STFC And RGLS Traded By Insiders

Jul 30, 2015 4:33 PM EDT

Insider Trading Alert - RYL, BHB And AAL Traded By Insiders

Mar 9, 2015 4:34 PM EDT

Today's Weak On High Volume Stock: Ocean Rig UDW (ORIG)

Mar 5, 2015 3:35 PM EST

Jones Lang LaSalle (JLL) Reaches New Lifetime High Today

Feb 9, 2015 4:32 PM EST

3 Basic Materials Stocks Driving The Sector Higher

Jan 30, 2015 4:32 PM EST

Dow Jones (DJIA) Today: Goldman Sachs Group (GS) Higher

Nov 20, 2014 3:33 PM EST

Oct 31, 2014 2:12 PM EDT

3 Hold-Rated Dividend Stocks: GHL, OKS, OAK

Oct 17, 2014 4:32 PM EDT

Oct 15, 2014 4:32 PM EDT

Oct 13, 2014 4:32 PM EDT

Looking at Mannkind's Afrezza Sales Estimates Ahead of Sanofi Earnings

Oct 7, 2014 11:39 AM EDT

Sep 23, 2014 4:31 PM EDT

Aug 28, 2014 4:32 PM EDT

Aug 26, 2014 4:33 PM EDT

Insider Trading Alert - UVE, WETF And ENPH Traded By Insiders

Aug 25, 2014 4:31 PM EDT

Aug 19, 2014 4:32 PM EDT

Insider Trading Alert - AEL, ANIP And CRM Traded By Insiders

Aug 19, 2014 4:32 PM EDT

Recent Articles from TheStreet

Zendesk IPO Ignores Selling, Pops 38% on First Day of Trading

INVESTING

ZEN

It said it plans to vote its shares against the issuance of Zendesk stock that would be needed to pay for the deal and could seek to replace board members.

JIM CRAMER

AMZN NOW TSLA

Jim Cramer says Fed's bond-buying statement compounded investor worries over Omicron.

INVESTING

HOOD ARKK ARKF

Robinhood said it had a data breach on Nov. 3 that exposed the data of 7 million or more of its customers.

New 'Spider-Man' Will Swing to the No. 1 Spot at the Box Office This Weekend

LIFESTYLE

SNE AMC DIS

AMC and other ticket websites temporarily crash on soaring demand for Spider-Man: No Way Home ticket sales, some of which were asking as much as $10,000 a pop.